Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$3.2 million.

  • Lipocine's Income towards Parent Company fell 4362.75% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year decrease of 3498.83%. This contributed to the annual value of $8352.0 for FY2024, which is 10005.11% up from last year.
  • As of Q3 2025, Lipocine's Income towards Parent Company stood at -$3.2 million, which was down 4362.75% from -$2.2 million recorded in Q2 2025.
  • Lipocine's 5-year Income towards Parent Company high stood at $12.6 million for Q4 2021, and its period low was -$6.8 million during Q2 2021.
  • For the 5-year period, Lipocine's Income towards Parent Company averaged around -$1.8 million, with its median value being -$2.6 million (2022).
  • Per our database at Business Quant, Lipocine's Income towards Parent Company surged by 37983.26% in 2021 and then plummeted by 17606.95% in 2023.
  • Quarter analysis of 5 years shows Lipocine's Income towards Parent Company stood at $12.6 million in 2021, then plummeted by 117.66% to -$2.2 million in 2022, then dropped by 2.35% to -$2.3 million in 2023, then surged by 178.09% to $1.8 million in 2024, then crashed by 278.82% to -$3.2 million in 2025.
  • Its Income towards Parent Company was -$3.2 million in Q3 2025, compared to -$2.2 million in Q2 2025 and -$1.9 million in Q1 2025.